echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > International Chemical > DSM sells protective materials business for more than 1.4 billion euros

    DSM sells protective materials business for more than 1.4 billion euros

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    DSM announced on April 20 that it will sell its protective materials business to Avient for a value of 1.


    The proposed transaction includes all of DSM's protective materials businesses, the most important of which are Dyneema, an ultra-high molecular weight polyethylene and the "world's strongest" man-made fiber


    In 2021, DSM's Protective Materials business will generate EUR 335 million in total sales and EBITDA of EUR 105 million


    DSM announced in September 2021 that it would explore a sale of its materials business as part of the company's plans to focus on health, nutrition and biosciences




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.